Establishment Labs Q3 revenue beats on Motiva sales in US
Overview
Establishment Labs Q3 revenue grows 33.8% yr/yr, beating analyst expectations
Adjusted EBITDA for Q3 turns positive, marking improvement from previous losses
Net loss and income from operations both beat analyst estimates
Outlook
Company raises 2025 revenue guidance to exceed $210 mln
Company expects 20% share of US breast augmentation market by year-end
Company anticipates exceeding $40 mln in US Motiva sales
Result Drivers
U.S. SALES GROWTH - Motiva sales in the U.S. contributed $11.9 mln to Q3 revenue, aiding overall revenue growth
GROSS MARGIN IMPROVEMENT - Gross margin rose to 70.1% from 63.9% due to geographic mix and higher selling prices
MINIMALLY INVASIVE PLATFORM - Co sees potential in minimally invasive platform to drive category growth and improve economics for surgeons
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $53.78 mln | $52.50 mln (8 Analysts) |
Q3 EPS | Beat | -$0.38 | -$0.52 (8 Analysts) |
Q3 Net Income | Beat | -$11.14 mln | -$15.20 mln (8 Analysts) |
Q3 Income From Operations | Beat | -$4.02 mln | -$9.75 mln (8 Analysts) |
Q3 Gross Profit | $37.69 mln | ||
Q3 Pretax Profit | -$10.72 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Establishment Labs Holdings Inc is $60.00, about 17.7% above its November 4 closing price of $49.40
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
